To fulfill the increasing demand for recombinant protein therapeutics, hundreds of millions of dollars have been invested by drug manufacturers and CMOs to develop the infrastructure required for culturing these cells in thousand litre scale-up.
Manufacturing accounts for a significant portion of the COGS for recombinant protein therapeutics, and so innovations that reduce timelines, increase yields, improve purity and decrease scale-up requirements represent key value propositions to drug developers. Greater than 70% of all recombinant protein therapeutics produced in mammalian cells are manufactured using Chinese Hamster Ovary (CHO) cell lines. The recent public release of the CHO genome sequence provides an opportunity to employ genetic engineering tools to enhance the ability of CHO cells to provide consistent, low-cost production of recombinant protein therapeutics to meet a growing demand.
Horizon’s precision cell line generation service uses our GENESIS™ platform for the routine modification of host mammalian genomes (including CHO) while maintaining cell line stability for significant improvements in selection, yield and timelines for biopharmaceutical manufacture.
Our custom host cell line engineering service delivers a fully engineered and characterized host cell line, and allows you to modify any gene at any locus in your proprietary host cell line.
Paragraph explaining benefits of Biocair×